Cargando…

Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension

BACKGROUND: Persistent pulmonary hypertension of the newborn (PPHN) is a serious neonatal problem which has a high mortality rate even with advanced modes of mechanical ventilation. Pentraxin 3 is one of the long pentraxins, which plays an essential role in regulation of cell proliferation and angio...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakeel, Maged A. El, Sabry, Rania N., El-kassas, Ghada M., El-Gaffar, Shereen A. Abd, batal, Wael H. El, Galal, Essam M., Azmy, Ashraf, Awadallah, Eman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Republic of Macedonia 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814462/
https://www.ncbi.nlm.nih.gov/pubmed/31666840
http://dx.doi.org/10.3889/oamjms.2019.638
_version_ 1783463005622632448
author Wakeel, Maged A. El
Sabry, Rania N.
El-kassas, Ghada M.
El-Gaffar, Shereen A. Abd
batal, Wael H. El
Galal, Essam M.
Azmy, Ashraf
Awadallah, Eman
author_facet Wakeel, Maged A. El
Sabry, Rania N.
El-kassas, Ghada M.
El-Gaffar, Shereen A. Abd
batal, Wael H. El
Galal, Essam M.
Azmy, Ashraf
Awadallah, Eman
author_sort Wakeel, Maged A. El
collection PubMed
description BACKGROUND: Persistent pulmonary hypertension of the newborn (PPHN) is a serious neonatal problem which has a high mortality rate even with advanced modes of mechanical ventilation. Pentraxin 3 is one of the long pentraxins, which plays an essential role in regulation of cell proliferation and angiogenesis. AIM: This study aims to assess serum pentraxin 3 levels in neonates with pulmonary arterial hypertension and compare them in those who have other congenital heart diseases and healthy neonates. Also, we intended to evaluate serum levels of CRP as a mediator of inflammation in the studied groups. METHODS: The study is a case-control study. Cases were recruited from El Galaa Teaching Hospital, classified into three groups; each group had thirty cases. The first one: cases with pulmonary hypertension (PHT), the second one: cases with congenital heart diseases (CHD) without pulmonary hypertension and the third group included healthy neonates. All participants were subjected to full history taking and full clinical examination. Diagnosis of congenital heart disease and pulmonary hypertension was made according to echocardiographic findings by pediatric cardiologist using echocardiography machine. Laboratory investigations included measurement of serum pentraxin 3, Routine CBC, CRP. RESULTS: This study found that the mean serum pentraxin 3 in PHT neonates was significantly higher than that of the control and CHD neonates (p ≤ 0.001, p = 0.02 respectively). Also, the mean Pentraxin3 of the CHD neonates was significantly higher than that of the control (p = 0.06). Also, the mean CRP of the PHT neonates was significantly higher than that of the control (p = 0.01). Regression analysis showed that Pentraxin3 was the main predictor of PAP (P = 0.01). CONCLUSION: Serum pentraxin 3 is significantly elevated in neonates with pulmonary hypertension, so measurement of pentraxin 3 levels in neonates may be valuable as a predictor for pulmonary hypertension in neonates.
format Online
Article
Text
id pubmed-6814462
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Republic of Macedonia
record_format MEDLINE/PubMed
spelling pubmed-68144622019-10-30 Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension Wakeel, Maged A. El Sabry, Rania N. El-kassas, Ghada M. El-Gaffar, Shereen A. Abd batal, Wael H. El Galal, Essam M. Azmy, Ashraf Awadallah, Eman Open Access Maced J Med Sci Clinical Science BACKGROUND: Persistent pulmonary hypertension of the newborn (PPHN) is a serious neonatal problem which has a high mortality rate even with advanced modes of mechanical ventilation. Pentraxin 3 is one of the long pentraxins, which plays an essential role in regulation of cell proliferation and angiogenesis. AIM: This study aims to assess serum pentraxin 3 levels in neonates with pulmonary arterial hypertension and compare them in those who have other congenital heart diseases and healthy neonates. Also, we intended to evaluate serum levels of CRP as a mediator of inflammation in the studied groups. METHODS: The study is a case-control study. Cases were recruited from El Galaa Teaching Hospital, classified into three groups; each group had thirty cases. The first one: cases with pulmonary hypertension (PHT), the second one: cases with congenital heart diseases (CHD) without pulmonary hypertension and the third group included healthy neonates. All participants were subjected to full history taking and full clinical examination. Diagnosis of congenital heart disease and pulmonary hypertension was made according to echocardiographic findings by pediatric cardiologist using echocardiography machine. Laboratory investigations included measurement of serum pentraxin 3, Routine CBC, CRP. RESULTS: This study found that the mean serum pentraxin 3 in PHT neonates was significantly higher than that of the control and CHD neonates (p ≤ 0.001, p = 0.02 respectively). Also, the mean Pentraxin3 of the CHD neonates was significantly higher than that of the control (p = 0.06). Also, the mean CRP of the PHT neonates was significantly higher than that of the control (p = 0.01). Regression analysis showed that Pentraxin3 was the main predictor of PAP (P = 0.01). CONCLUSION: Serum pentraxin 3 is significantly elevated in neonates with pulmonary hypertension, so measurement of pentraxin 3 levels in neonates may be valuable as a predictor for pulmonary hypertension in neonates. Republic of Macedonia 2019-08-14 /pmc/articles/PMC6814462/ /pubmed/31666840 http://dx.doi.org/10.3889/oamjms.2019.638 Text en Copyright: © 2019 Maged A. El Wakeel, Rania N. Sabry, Ghada M. El-kassas, Shereen A. Abd El-Gaffar, Wael H. El batal, Essam M. Galal, Ashraf Azmy, Eman Awadallah. http://creativecommons.org/licenses/CC BY-NC/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
spellingShingle Clinical Science
Wakeel, Maged A. El
Sabry, Rania N.
El-kassas, Ghada M.
El-Gaffar, Shereen A. Abd
batal, Wael H. El
Galal, Essam M.
Azmy, Ashraf
Awadallah, Eman
Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension
title Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension
title_full Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension
title_fullStr Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension
title_full_unstemmed Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension
title_short Pentraxin 3: A Potential Novel Predictor for Neonatal Pulmonary Hypertension
title_sort pentraxin 3: a potential novel predictor for neonatal pulmonary hypertension
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814462/
https://www.ncbi.nlm.nih.gov/pubmed/31666840
http://dx.doi.org/10.3889/oamjms.2019.638
work_keys_str_mv AT wakeelmagedael pentraxin3apotentialnovelpredictorforneonatalpulmonaryhypertension
AT sabryranian pentraxin3apotentialnovelpredictorforneonatalpulmonaryhypertension
AT elkassasghadam pentraxin3apotentialnovelpredictorforneonatalpulmonaryhypertension
AT elgaffarshereenaabd pentraxin3apotentialnovelpredictorforneonatalpulmonaryhypertension
AT batalwaelhel pentraxin3apotentialnovelpredictorforneonatalpulmonaryhypertension
AT galalessamm pentraxin3apotentialnovelpredictorforneonatalpulmonaryhypertension
AT azmyashraf pentraxin3apotentialnovelpredictorforneonatalpulmonaryhypertension
AT awadallaheman pentraxin3apotentialnovelpredictorforneonatalpulmonaryhypertension